ERBB2 and breast cancer: Similarly, the expansion of what physicians consider HER2+ for therapeutic purposes (HER2-low and HER2-ultra-low tumors) [4] has led to therapeutic overlap, wherein patients with similar breast cancer subsets may receive both agents.